Staff Contact: Kara Amann-Kale or Keri Barclay
The FDA issued an EUA for Novavax’s COVID-19 vaccine in individuals 18 years of age and older. This vaccine uses a different type of technology than the other three approved COVID-19 vaccines. Novavax is a two-dose protein-based vaccine that uses harmless protein fragments of the SARS-CoV-2 virus to mount an immune response and protection against COVID-19. The more traditional nature of the vaccine may appeal to populations that have been hesitant to receive an mRNA vaccine. The CDC Advisory Committee on Immunizations is scheduled to meet on Tuesday, July 19 and must give their approval, in addition to CDC approval, before administration of this new vaccine may begin.